secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001140361-25-030297
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants
--------------------------------------------------------------------------------

- Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.
- 130 patients implanted with DurAVR THV since start; 21 in Q2 2025; 79 clinical sites qualified for PARADIGM trial.
- R&D expenses $16.3M in Q2 on PARADIGM trial preparation and manufacturing scale-up.
- Cash and equivalents $28.4M at June 30, 2025; net operating cash outflow $41.0M in H1 2025.
- No dividend declared; board appointed two new directors David Roberts and Gregory Moss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/0001140361-25-030297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/ef20053645_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-030297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer